GlassScriptPhysician profile
Scott Alan Kristie
NPI 1548576838
$1,403.14
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $526 · 2024: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.36 | 2023-2024 | |
| Corium, LLC | $151.18 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $134.10 | 2023-2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $103.84 | 2023-2024 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $99.81 | 2024 | Spravato |
| Lundbeck LLC | $73.60 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $71.89 | 2023-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $69.98 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $62.75 | 2023-2024 | Dyanavel Xr |
| Sage Therapeutics, LLC | $60.81 | 2024 | |
| Neurocrine Biosciences, INC. | $52.49 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $42.16 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Indivior INC. | $39.44 | 2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $38.04 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $31.69 | 2024 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kristie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.